US Pseudotumor Cerebri Market

ID: MRFR/Pharma/17500-HCR 100 Pages Vikita Thakur Last Updated: September 10, 2026
US Pseudotumor Cerebri Market Research Report By Diagnosis (fundoscopy, lumbar puncture, neuroimaging, others), By Treatment (surgery, medication, spinal fluid shunt, optic nerve sheath fenestration, dural venous sinus stenting, bariatric surgery), By Medication (acetazolamide, furosemide, steroids, topiramate) and By End User (hospitals, diagnostic centers, clinics, drug stores, pharmacies, others) - Growth & Industry Forecast 2025 To 2035
US Pseudotumor Cerebri Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.33%
2024 Market Size$ 850 Million
2025 Market Size$ 912.3 Million
2035 Market Size$ 1,850 Million
Key Players
Novartis
Roche
Bristol-Myers Squibb
Pfizer
Eli Lilly
Teva Pharmaceutical Industries
Trends
  • Rising Awareness and Diagnosis
  • Innovative Treatment Approaches
  • Patient-Centric Care Models
Opportunities
  • Increasing Incidence of Obesity
  • Enhanced Patient Education Initiatives
  • Advancements in Diagnostic Technologies
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Diagnosis (USD Million)
      1. 4.1.1 Fundoscopy
      2. 4.1.2 Lumbar Puncture
      3. 4.1.3 Neuroimaging
      4. 4.1.4 Others
    2. 4.2 Chemicals and Materials, BY Treatment (USD Million)
      1. 4.2.1 Surgery
      2. 4.2.2 Medication
      3. 4.2.3 Spinal Fluid Shunt
      4. 4.2.4 Optic Nerve Sheath Fenestration
      5. 4.2.5 Dural Venous Sinus stenting
      6. 4.2.6 Bariatric Surgery
    3. 4.3 Chemicals and Materials, BY Medication (USD Million)
      1. 4.3.1 Acetazolamide
      2. 4.3.2 Furosemide
      3. 4.3.3 Steroids
      4. 4.3.4 Topiramate
    4. 4.4 Chemicals and Materials, BY End-User (USD Million)
      1. 4.4.1 Hospitals
      2. 4.4.2 Diagnostic Centers
      3. 4.4.3 Clinics
      4. 4.4.4 Drug stores
      5. 4.4.5 Pharmacies
      6. 4.4.6 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novartis (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Roche (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Bristol-Myers Squibb (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Pfizer (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Eli Lilly (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Teva Pharmaceutical Industries (IL)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AstraZeneca (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Sanofi (FR)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Merck & Co. (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY DIAGNOSIS
    3. 6.3 US MARKET ANALYSIS BY TREATMENT
    4. 6.4 US MARKET ANALYSIS BY MEDICATION
    5. 6.5 US MARKET ANALYSIS BY END-USER
    6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    12. 6.12 CHEMICALS AND MATERIALS, BY DIAGNOSIS, 2024 (% SHARE)
    13. 6.13 CHEMICALS AND MATERIALS, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
    14. 6.14 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 (% SHARE)
    15. 6.15 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 TO 2035 (USD Million)
    16. 6.16 CHEMICALS AND MATERIALS, BY MEDICATION, 2024 (% SHARE)
    17. 6.17 CHEMICALS AND MATERIALS, BY MEDICATION, 2024 TO 2035 (USD Million)
    18. 6.18 CHEMICALS AND MATERIALS, BY END-USER, 2024 (% SHARE)
    19. 6.19 CHEMICALS AND MATERIALS, BY END-USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
      3. 7.2.3 BY MEDICATION, 2025-2035 (USD Million)
      4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Pseudotumor Cerebri Market Segmentation

US Pseudotumor Cerebri Market By Diagnosis (USD Million, 2025-2035)

  • Fundoscopy
  • Lumbar Puncture
  • Neuroimaging
  • Others

US Pseudotumor Cerebri Market By Treatment (USD Million, 2025-2035)

  • Surgery
  • Medication
  • Spinal Fluid Shunt
  • Optic Nerve Sheath Fenestration
  • Dural Venous Sinus stenting
  • Bariatric Surgery

US Pseudotumor Cerebri Market By Medication (USD Million, 2025-2035)

  • Acetazolamide
  • Furosemide
  • Steroids
  • Topiramate

US Pseudotumor Cerebri Market By End-User (USD Million, 2025-2035)

  • Hospitals
  • Diagnostic Centers
  • Clinics
  • Drug stores
  • Pharmacies
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.